Precipio (PRPO) Q2 2026 earnings review
Record Top-Line and Cash Flow Mask Growing Stock Comp Dilution
Precipio delivered a record revenue quarter of $7.0M (+22% YoY) and generated positive operating cash flow of $0.7M. The high-margin Products division re-accelerated to $0.9M, bouncing back from Q1 shipping delays. Management highlighted a return to positive Adjusted EBITDA of $0.4M. However, investors must look past the headline Non-GAAP numbers: GAAP Net Income actually reversed from a $0.1M profit a year ago to a $0.2M loss this quarter, entirely driven by stock-based compensation doubling to $0.8M. The core operational engine is working and achieving self-sufficiency, but equity holders are footing the bill.
🐂 Bull Case
Generated $0.7M in operating cash flow, growing the cash balance to >$3M without a financing event. The days of defensive capital preservation appear to be effectively over.
Product revenue surged 21% past its previous Q4-25 high to hit $0.9M. The newly hired commercial team is successfully transitioning pipeline into go-lives.
🐻 Bear Case
Management trumpets a return to positive Adjusted EBITDA, but GAAP Net Income flipped negative YoY due to heavy stock-based compensation.
Q2 results benefited from an $80K product shipment that slipped from late March (Q1) into April. The onboarding cycle for new clinical labs remains highly unpredictable.
⚖️ Verdict: ⚪
Cautiously Bullish. The operational execution is solid—growing top-line and generating cash without toxic financings is exactly what this microcap needed. However, the aggressive use of Adjusted EBITDA to mask a doubling in stock-based compensation is a red flag that tempers excitement.
Key Themes
Stock-Based Comp Contradicts Profitability Narrative
Management heavily promoted a $0.6M sequential swing to positive $0.4M Adjusted EBITDA. However, this metric completely ignores the fact that Stock-Based Compensation expense doubled YoY from $0.4M to $0.8M. This non-cash expense was the primary reason GAAP Net Income decelerated from a $0.1M profit in 25Q2 to a $0.2M loss in 26Q2. While the company isn't burning hard cash, it is burning equity at an accelerating rate to fund its operations.
Products Division Accelerating to New Highs
Product revenue (featuring HemeScreen and Bloodhound technologies) hit a record $0.9M, up from $0.66M in Q1 and surpassing the previous Q4-25 high of $0.75M. While this number benefited slightly from an $80K order that slipped from Q1, it validates that the expanded commercial team hired in January is converting its pipeline into active go-lives. This division remains the primary engine for future margin expansion.
Stable Pathology Cash Engine
Pathology services revenue proved stable, growing sequentially from $6.0M in Q1 to $6.1M in Q2. This division continues to act as the financial backbone of the company, generating the bulk of the $0.7M in operating cash flow used to fund the Products division's commercial expansion.
Commercial Pipeline Conversion
The dedicated 3-person commercial team, hired at the start of the year, is paying dividends. In Q1, they identified $3M in new annualized revenue potential. The Q2 spike in product revenue indicates successful execution in moving customers through complex IT and regulatory validation hurdles to actual testing.
Reimbursement Pressures from CMS (Macro)
The Pathology division is still operating under the shadow of a macro headwind: the 2026 CMS fee schedule implemented an 8% cut to flow cytometry rates early in the year, costing Precipio approximately $125K in gross profit in Q1 alone. Management's ability to drive cost efficiencies to offset these government-mandated rate cuts remains a permanent, ongoing operational burden.
Customer Onboarding and Revenue Timing Volatility
Reversing quarter-to-quarter revenue misses remains a risk. The transition of customers from 'ready' to 'live' is fraught with uncontrollable delays—ranging from hospital committee meetings to machine downtime. The $80K swing between Q1 and Q2 highlights that product revenue will remain lumpy and difficult to forecast until the customer base scales significantly.
Other KPIs
Accelerating. Generating strong positive operating cash flow enabled Precipio to end the quarter with over $3M in the bank, up from $1.1M in the prior year period. This secures their self-sustainability claim and limits immediate dilution risk from secondary offerings.
Reversing. Bounced back to positive territory after dipping to $(0.2)M in Q1-26. The improvement was driven by higher top-line revenues, though heavily adjusted for stock-based compensation.
Key Questions
Normalized Stock-Based Compensation
Stock-based compensation doubled year-over-year to $0.8 million, entirely erasing GAAP net income. What is the expected run-rate for this expense, and at what revenue level will GAAP net income turn sustainably positive?
Product Revenue Composition
Of the $0.9 million in Q2 Product Revenue, how much was directly attributable to the $80,000 delayed shipment from Q1 versus organic adoption from the newly generated commercial pipeline?
Pathology Margin Recovery
Following the 8% CMS rate cut to flow cytometry that impacted Q1 margins, have cost-cutting initiatives fully offset this headwind, and are Pathology gross margins back to historical averages?